A phase I/IIa trial to investigate DTX-201 for haemophilia A
Phase of Trial: Phase I/II
Latest Information Update: 27 Jun 2016
At a glance
- Drugs DTX 201 (Primary)
- Indications Haemophilia A
- Focus Adverse reactions
- Sponsors Bayer
- 27 Jun 2016 According to a Dimension Therapeutics media release, the company anticipates IND filing early 2018 in collaboration with Bayer for the treatment of moderate/severe to severe hemophilia A, and expect initial data from the trial in 2018.
- 29 Mar 2016 New trial record
- 24 Mar 2016 IND-enabling studies are expected in 2016, according to a Dimension Therapeutics media release.